

Angelo Sangiovanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7179728/publications.pdf>

Version: 2024-02-01

76
papers

6,620
citations

87888

38
h-index

95266

68
g-index

78
all docs

78
docs citations

78
times ranked

7439
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
2	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. <i>Journal of Hepatology</i> , 2022, 76, 302-310.	3.7	48
3	Prothrombin induced by vitamin K absence or antagonist and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 350-359.	3.7	11
4	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
5	An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 109.	2.4	0
6	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 64.	1.1	2
7	Reshape and secure HCC managing during COVID-19 pandemic: A single centre analysis of four periods in 2020 versus 2019. <i>Liver International</i> , 2021, 41, 3028-3032.	3.9	5
8	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	3.7	13
9	Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 568-574.	1.0	40
10	Transjugular liver biopsy: The Tru-cut needle might be better for stiffer livers. <i>Digestive and Liver Disease</i> , 2020, 52, 1381-1382.	0.9	0
11	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3583.	3.7	16
12	Hepatic Fat Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. <i>Hepatology</i> , 2020, 72, 1912-1923.	7.3	48
13	Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e128-e129.	1.9	1
14	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	3.7	38
15	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , 2020, 40, 1987-1996.	3.9	44
16	Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.	3.9	11
17	Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. <i>Annals of Hepatology</i> , 2019, 18, 318-324.	1.5	4
18	Deficient Natural Killer Cell NKG2D-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	7.3	48

#	ARTICLE	IF	CITATIONS
19	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1183-1191.e7.	4.4	79
20	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <scp>IFN</scp> and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	3.9	22
21	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. <i>Journal of Hepatology</i> , 2018, 68, 485-492.	3.7	195
22	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Hepatology</i> , 2018, 17, 110-118.	1.5	20
23	Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 202-205.	1.5	0
24	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 15350-15364.	1.8	79
25	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	3.8	54
26	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	3.9	25
27	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.9	41
28	Premalignant and Early Malignant Hepatocellular Lesions in Chronic Hepatitis/Cirrhosis. , 2018, , 487-505.		1
29	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	16.8	172
30	Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. <i>Liver International</i> , 2016, 36, 166-176.	3.9	19
31	Treatment of hepatocellular carcinoma: beyond international guidelines. <i>Liver International</i> , 2016, 36, 124-129.	3.9	67
32	A therapeutic conundrum: Delaying ablation of small nonresectable early hepatocellular carcinoma to facilitate liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 161-162.	2.4	2
33	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>United European Gastroenterology Journal</i> , 2016, 4, 363-370.	3.8	16
34	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	12.1	108
35	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan status in patients with a small hepatocellular carcinoma. <i>Liver Transplantation</i> , 2015, 21, 1259-1269.	2.4	35
36	Treatment of hepatocellular carcinoma: beyond international guidelines. <i>Liver International</i> , 2015, 35, 129-138.	3.9	93

#	ARTICLE	IF	CITATIONS
37	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Digestive Diseases, 2015, 33, 735-744.	1.9	19
38	Hepatitis B virus (<scp>HBV</scp>) <scp>DNA</scp> integration in patients with occult <scp>HBV</scp> infection and hepatocellular carcinoma. Liver International, 2015, 35, 2311-2317.	3.9	92
39	A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. Journal of Hepatology, 2015, 63, 1323-1333.	3.7	22
40	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	12.1	70
41	Vitamin D deficiency and liver cancer: More than just an epidemiological association?. Hepatology, 2014, 60, 1130-1132.	7.3	14
42	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 995-1001.	3.7	61
43	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
44	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Journal of Hepatology, 2013, 58, 1188-1193.	3.7	110
45	Advanced precancerous lesions in the liver. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 269-284.	2.4	46
46	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Digestive and Liver Disease, 2013, 45, 43-49.	0.9	23
47	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver International, 2013, 33, 771-779.	3.9	91
48	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	2.5	42
49	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 2012, 57, 821-829.	3.7	736
50	Re: Indeterminate 1-2 cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?. Hepatology, 2012, 55, 651-651.	7.3	0
51	Guidelines for the management of hepatocellular carcinoma: still in need of standardization. Chinese Clinical Oncology, 2012, 1, 15.	1.2	0
52	How I manage my patients with hepatocellular carcinoma. Liver International, 2011, 31, 145-150.	3.9	2
53	Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology, 2011, 53, 1549-1557.	7.3	77
54	Surveillance for hepatocellular carcinoma: A standard of care, not a clinical option. Hepatology, 2011, 54, 1898-1900.	7.3	12

#	ARTICLE	IF	CITATIONS
55	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. <i>Hepatology</i> , 2010, 52, 1723-1730.	7.3	67
56	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. <i>Gut</i> , 2010, 59, 638-644.	12.1	358
57	Transarterial Chemoembolization with Epirubicin-eluting Beads versus Transarterial Embolization before Liver Transplantation for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 327-332.	0.5	132
58	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 50, 746-754.	3.7	280
59	A 28-Year Study of the Course of Hepatitis B Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 136, 1629-1638.	1.3	285
60	Epidemiology of the Hepatocellular Carcinoma. , 2009, , 1-8.		1
61	Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. <i>Hepatology</i> , 2007, 47, 357-357.	7.3	2
62	The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. <i>Hepatology</i> , 2006, 43, 1303-1310.	7.3	527
63	Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 35, 27-32.	1.4	24
64	The strategic role of staging in the treatment of HCC. <i>Hepatology</i> , 2004, 39, 552-553.	7.3	10
65	Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. <i>Gastroenterology</i> , 2004, 126, 1005-1014.	1.3	556
66	Etiology, natural history and treatment of hepatocellular carcinoma. <i>Antiviral Research</i> , 2003, 60, 145-150.	4.1	64
67	Segmental Transcatheter Arterial Chemoembolization Treatment in Patients with Cirrhosis and Inoperable Hepatocellular Carcinomas. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, 995-999.	0.5	31
68	Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 501-506.	1.6	30
69	Hepatocyte Proliferation and Risk of Hepatocellular Carcinoma in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2001, 96, 1575-1580.	0.4	38
70	High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. <i>Hepatology</i> , 1999, 29, 1704-1707.	7.3	87
71	Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study. <i>Hepatology</i> , 1998, 27, 853-856.	7.3	89
72	HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. <i>Journal of Hepatology</i> , 1998, 29, 701-706.	3.7	74

#	ARTICLE	IF	CITATIONS
73	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. Journal of Hepatology, 1996, 25, 474-480.	3.7	49
74	Hepatocellular Carcinoma in Italian Patients with Cirrhosis. New England Journal of Medicine, 1991, 325, 675-680.	27.0	773
75	Specificity of the Hepatitis C Virus Antibody ELISA in Patients With Hepatocellular Carcinoma. Journal of the National Cancer Institute, 1990, 82, 1784-1785.	6.3	3
76	Î²-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology, 1989, 9, 433-438.	7.3	106